Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Michael, Emig"'
Autor:
Montserrat Arnan, Pau Montesinos, Stéphane de Botton, Christian Recher, Lydia Wunderle, Michael Emig, Andreas Harstrick, Kerstin Pietzko, Sheena Pinto, Paulien Ravenstijn, Naval Daver
Publikováno v:
HemaSphere, Vol 7, p e2404792 (2023)
Externí odkaz:
https://doaj.org/article/b4d7a74d16094c5d9e7ece66f935eeac
Autor:
Won-Seog Kim, Jake Shortt, Pier Luigi Zinzani, Natalya Mikhaylova, Ana Marin-Niebla, Dejan Radeski, Vincent Ribrag, Eva Domingo Domènech, Ahmed Sawas, Karenza Alexis, Michael Emig, Linta Garcia, Andre Overesch, Kerstin Pietzko, Steven Horwitz
Publikováno v:
HemaSphere, Vol 7, p e6843062 (2023)
Externí odkaz:
https://doaj.org/article/70ae321f2d424a66bbf78d0f537758bb
Autor:
Won Seog Kim, Jake Shortt, Pier Luigi Zinzani, Natalya Mikhaylova, Ana Marin-Niebla, Dejan Radeski, Vincent Ribrag, Eva Domingo Domenech, Ahmed Sawas, Karenza Alexis, Michael Emig, Linta Garcia, Andre Overesch, Kerstin Pietzko, Steven Horwitz
Publikováno v:
Cancer Research. 83:CT024-CT024
PTCLs are aggressive hematologic malignancies often with poor prognoses; for patients with R/R PTCL there is no standard-of-care therapy and novel treatments are required. AFM13 is a tetravalent, bispecific Innate Cell Engager (ICE ® ) that binds CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e5b18de21a3793af1f3559926215c9d
https://doi.org/10.1158/1538-7445.am2023-ct024
https://doi.org/10.1158/1538-7445.am2023-ct024
Autor:
Gabriele Hintzen, Susanne Wingert, Michael Emig, Pilar Nava-Parada, Kerstin Pietzko, Laura Kohlhas, Uwe Reusch, Melissa Berrien-Elliott, Todd Fehniger, Mark Foster, Paolo Nuciforo, Ester Castillo Andreo, Sina Staeble, Paulien Ravenstijn, Bettina Rehbein, Erich Rajkovic, Arndt Schottelius, Joachim Koch
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4857f1d8e32d5111d555caf680b9198
https://doi.org/10.1136/jitc-2022-sitc2022.0729
https://doi.org/10.1136/jitc-2022-sitc2022.0729
Autor:
Yago Nieto, Pinaki P Banerjee, Indreshpal Kaur, Lori Griffin, Christina Ganesh, Lucila Kerbauy, Rafet Basar, Mecit Kaplan, Sanjida Islam, Daniel Esqueda, Roland Bassett, Melissa Timmons, Jeremy L. Ramdial, Samer A Srour, Neeraj Saini, Chitra Hosing, Sairah Ahmed, Swaminathan Padmanabhan Iyer, Karenza Alexis, Michael Emig, Andreas Harstrick, Elizabeth J Shpall, Katy Rezvani
Publikováno v:
Blood. 140:415-416
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3107cd8452d95fbf1c9b9ee94d8251fd
https://doi.org/10.1182/blood-2022-156125
https://doi.org/10.1182/blood-2022-156125
Autor:
Anthony El-Khoueiry, Juanita Lopez, Omar Saavedra, Mark Awad, Jacob Thomas, Crescens Tiu, Elena Garralda, Bettina Rehbein, Gabriele Hintzen, Kerstin Pietzko, Christa Raab, Erich Rajkovic, Paulien Ravenstijn, Michael Emig
Publikováno v:
Cancer Research. 82:CT149-CT149
AFM24 is a first-in-class, tetravalent, bispecific ICE® that binds to EGFR on tumor cells and CD16A on natural killer (NK) cells and macrophages, inducing antibody-mediated cytotoxicity and antibody-mediated phagocytosis, respectively. Preclinical i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71d302db23b3459f4bbde26f370f2b46
https://doi.org/10.1158/1538-7445.am2022-ct149
https://doi.org/10.1158/1538-7445.am2022-ct149
Autor:
Michael Emig, Sang Cheul Oh, Maria Luisa Limon Miron, Sumitra Ananda, Gunnar Folprecht, Eric Van Cutsem, Astra M. Liepa, György Bodoky, Jaffer A. Ajani, Stefano Cascinu, Zev A. Wainberg, Gustavo Girotto, Kei Muro, R. Wei, Roberto Carlesi, Atsushi Ohtsu
Publikováno v:
Oncologist
The oncologist, vol 26, iss 3
The oncologist, vol 26, iss 3
Background In the intent-to-treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::312b42ea28ef1f39a06a0e4029ea8ca6
https://lirias.kuleuven.be/handle/123456789/670880
https://lirias.kuleuven.be/handle/123456789/670880
Autor:
Omar Saavedra Santa Gadea, Elena Garralda, Juanita Suzanne Lopez, Mark M. Awad, Jacob Stephen Thomas, Crescens Diane Tiu, Daniela Morales-Espinosa, Christa Raab, Bettina Rehbein, Gabriele Hintzen, Kerstin Pietzko, Paulien Ravenstijn, Michael Emig, Anthony B. El-Khoueiry
Publikováno v:
Journal of Clinical Oncology. 40:TPS2672-TPS2672
TPS2672 Background: AFM24 is a first-in-class, tetravalent, bispecific, fragment crystallizable-silenced antibody that targets epidermal growth factor receptor-expressing (EGFR+) solid tumors. Of its 4 binding sites, 2 are specific for EGFR, and 2 ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4560271e9ef9f652ce9d4e18733c9232
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2672
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2672
Autor:
Anthony B. El-Khoueiry, Paul Y. Song, Jennifer Rubel, Dorna Y. Pourang, Christa Raab, Gabriele Hintzen, Michael Emig, Pilar Nava-Parada
Publikováno v:
Journal of Clinical Oncology. 40:TPS2675-TPS2675
TPS2675 Background: Natural killer (NK) cells are a critical component of the innate immune system involved in the eradication of transformed cells via antibody-dependent cellular cytotoxicity (ADCC). For treatment of solid tumors autologous NK cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91c2d924616bb9285f9dfbf918f2b8d5
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2675
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2675
Autor:
Josep Tabernero, Yee Chao, Ian Chau, Lucas Vieira dos Santos, Michael Emig, Eric Van Cutsem, Stefano Cascinu, John Zalcberg, Kei Muro, Rebecca Cheng, Jae Yong Cho, Yanzhi Hsu, Mauro Orlando, Charles S. Fuchs, Yasuhiro Shimada, Eldar Topuzov, Chanchal Goswami, György Bodoky
Publikováno v:
Journal of Gastroenterology and Hepatology. 33:814-824
Background and Aim REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. We describe exploratory subgroup analyses to assess the efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a23319e0b0a7a79b04f258208f34b292
https://doi.org/10.1111/jgh.14007
https://doi.org/10.1111/jgh.14007